{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:18:43Z","timestamp":1792019923215,"version":"4.4.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T00:00:00Z","timestamp":1779580800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Obesity Pillars"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.obpill.2026.100278","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T23:21:25Z","timestamp":1779751285000},"page":"100278","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Patient preferences for pharmacological treatments for obesity: The VOICE study"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1584-1146","authenticated-orcid":false,"given":"Christy","family":"Houle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Gelhorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelyn","family":"Cutts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Samuelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neena","family":"Xavier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.obpill.2026.100278_bib1","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1136\/jamia.1998.0050257","article-title":"Improving health care by understanding patient preferences: the role of computer technology","volume":"5","author":"Brennan","year":"1998","journal-title":"J Am Med Inform Assoc"},{"key":"10.1016\/j.obpill.2026.100278_bib2","series-title":"Committee on quality of health care in America. Crossing the quality chasm: a new health system for the 21st century","year":"2001"},{"issue":"1","key":"10.1016\/j.obpill.2026.100278_bib3","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00198-011-1780-1","article-title":"Final results of the DAPS (denosumab adherence preference satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women","volume":"23","author":"Freemantle","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.obpill.2026.100278_bib4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.33393\/dti.2021.2342","article-title":"The role of patient preferences in adherence to treatment in chronic disease: a narrative review","volume":"15","author":"Losi","year":"2021","journal-title":"Drug Target Insights"},{"issue":"9","key":"10.1016\/j.obpill.2026.100278_bib5","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1007\/s00198-014-2756-8","article-title":"Clinical efficacy and treatment persistence of monthly minodronate for osteoporotic patients unsatisfied with, and shifted from, daily or weekly bisphosphonates: the BP-MUSASHI study","volume":"25","author":"Sakai","year":"2014","journal-title":"Osteoporos Int"},{"issue":"8","key":"10.1016\/j.obpill.2026.100278_bib6","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.4158\/EP171866.GL","article-title":"American association of clinical endocrinologists and American college of endocrinology protocol for standardized production of clinical practice guidelines, algorithms, and checklists\u20132017 update","volume":"23","author":"Mechanick","year":"2017","journal-title":"Endocr Pract"},{"key":"10.1016\/j.obpill.2026.100278_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP161365.GL","article-title":"American association of clinical endocrinologists and American college of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity","volume":"22","author":"Garvey","year":"2016","journal-title":"Endocr Pract"},{"key":"10.1016\/j.obpill.2026.100278_bib8","first-page":"1","article-title":"Factors that determine patients considering medication for the disease of obesity: an IMI2 SOPHIA study","author":"Craig","year":"2024","journal-title":"Int J Obes"},{"key":"10.1016\/j.obpill.2026.100278_bib9","series-title":"Campbell, CA: vivus","year":"2012"},{"key":"10.1016\/j.obpill.2026.100278_bib10","series-title":"Xenical [package insert]","year":"2022"},{"key":"10.1016\/j.obpill.2026.100278_bib11","series-title":"Nalpropion pharmaceuticals","author":"Brentwood","year":"2022"},{"key":"10.1016\/j.obpill.2026.100278_bib12","series-title":"Bagsvaerd, Denmark: novo nordisk A\/S","year":"2023"},{"issue":"3","key":"10.1016\/j.obpill.2026.100278_bib13","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.obpill.2026.100278_bib14","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"9741","key":"10.1016\/j.obpill.2026.100278_bib15","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(10)60888-4","article-title":"Effect of naltrexone plus bupropion on weight loss in overweight and Obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"376","author":"Greenway","year":"2010","journal-title":"Lancet"},{"issue":"9774","key":"10.1016\/j.obpill.2026.100278_bib16","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60205-5","article-title":"Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and Obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Gadde","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.obpill.2026.100278_bib17","series-title":"Wegovy. Prescribing information","year":"2024"},{"key":"10.1016\/j.obpill.2026.100278_bib18","series-title":"Zepbound. Prescribing information","year":"2024"},{"issue":"2","key":"10.1016\/j.obpill.2026.100278_bib19","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/dom.14244","article-title":"Patients' preferences for once-daily oral versus once-weekly injectable diabetes medications: the REVISE study","volume":"23","author":"Boye","year":"2021","journal-title":"Diabetes Obes Metabol"},{"issue":"3","key":"10.1016\/j.obpill.2026.100278_bib20","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1177\/0145721706288182","article-title":"Understanding diabetes medications from the perspective of patients with type 2 diabetes: prerequisite to medication concordance","volume":"32","author":"Hayes","year":"2006","journal-title":"Diabetes Educat"},{"issue":"7","key":"10.1016\/j.obpill.2026.100278_bib21","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/j.clinthera.2016.05.009","article-title":"Self-reported barriers to adherence and persistence to treatment with injectable medications for type 2 diabetes","volume":"38","author":"Spain","year":"2016","journal-title":"Clin Ther"},{"issue":"1","key":"10.1016\/j.obpill.2026.100278_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40271-012-0001-0","article-title":"Social stigma in diabetes : a framework to understand a growing problem for an increasing epidemic","volume":"6","author":"Schabert","year":"2013","journal-title":"Patient"},{"issue":"1","key":"10.1016\/j.obpill.2026.100278_bib23","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12875-018-0753-2","article-title":"Perceptions of insulin use in type 2 diabetes in primary care: a thematic synthesis","volume":"19","author":"Ellis","year":"2018","journal-title":"BMC Fam Pract"},{"issue":"2","key":"10.1016\/j.obpill.2026.100278_bib24","doi-asserted-by":"crossref","first-page":"240","DOI":"10.2337\/dc09-1348","article-title":"Correlates of insulin injection omission","volume":"33","author":"Peyrot","year":"2010","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.obpill.2026.100278_bib25","doi-asserted-by":"crossref","first-page":"94","DOI":"10.5152\/eurjrheum.2019.18182","article-title":"Survey on transportation and storage of biological therapies by patients","volume":"6","author":"Saavedra","year":"2019","journal-title":"Eur J Rheumatol"},{"key":"10.1016\/j.obpill.2026.100278_bib26","series-title":"Efficacy and safety of oral semaglutide 25 mg in adults with overweight\/obesity: the OASIS 4 RCT","author":"Garvey","year":"2024"},{"issue":"10","key":"10.1016\/j.obpill.2026.100278_bib27","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa2302392","article-title":"Daily oral GLP-1 receptor agonist orforglipron for adults with obesity","volume":"389","author":"Wharton","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.obpill.2026.100278_bib28","year":"2025","journal-title":"Diabetes"},{"issue":"47","key":"10.1016\/j.obpill.2026.100278_bib29","doi-asserted-by":"crossref","first-page":"29959","DOI":"10.1073\/pnas.2014879117","article-title":"Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist","volume":"117","author":"Kawai","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"10.1016\/j.obpill.2026.100278_bib30","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1111\/dom.15150","article-title":"Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: a phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes","volume":"25","author":"Pratt","year":"2023","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.obpill.2026.100278_bib31","series-title":"Foundayo. Prescribing information","year":"2026"},{"issue":"3","key":"10.1016\/j.obpill.2026.100278_bib32","doi-asserted-by":"crossref","DOI":"10.1111\/cob.12309","article-title":"A call to action to inform patient\u2010centred approaches to obesity management: development of a disease\u2010illness model","volume":"9","author":"Fastenau","year":"2019","journal-title":"Clin Obes"},{"issue":"1","key":"10.1016\/j.obpill.2026.100278_bib33","first-page":"11","article-title":"Person-centred obesity care\u2013techniques, thresholds, tools and targets","volume":"16","author":"Kalra","year":"2020","journal-title":"Eur Endocrinol"},{"key":"10.1016\/j.obpill.2026.100278_bib35","author":"Halsey"},{"issue":"10400","key":"10.1016\/j.obpill.2026.100278_bib36","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0140-6736(23)01302-8","article-title":"Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study","volume":"402","author":"Frias","year":"2023","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.obpill.2026.100278_bib34","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1080\/01441640902827623","article-title":"Constructing efficient stated choice experimental designs","volume":"29","author":"Rose","year":"2009","journal-title":"Transp Rev"},{"issue":"12","key":"10.1016\/j.obpill.2026.100278_bib38","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1002\/oby.22954","article-title":"Diagnosing obesity as a first step to weight loss: an observational study","volume":"28","author":"Ciemins","year":"2020","journal-title":"Obesity"},{"issue":"Supplement_1","key":"10.1016\/j.obpill.2026.100278_bib39","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvad114.112","article-title":"SAT664 obesity and overweight diagnosis, physician prescription and patient filling of anti-obesity medications in US","volume":"7","author":"Ezendu","year":"2023","journal-title":"J Endocr Soc"},{"issue":"11","key":"10.1016\/j.obpill.2026.100278_bib40","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-017583","article-title":"Prevalence and recognition of obesity and its associated comorbidities: cross-sectional analysis of electronic health record data from a large US integrated health system","volume":"7","author":"Pantalone","year":"2017","journal-title":"BMJ Open"},{"issue":"7","key":"10.1016\/j.obpill.2026.100278_bib41","first-page":"527","article-title":"Dosing frequency and medication adherence in chronic disease","volume":"18","author":"Coleman","year":"2012","journal-title":"J Manag Care Pharm"},{"issue":"5","key":"10.1016\/j.obpill.2026.100278_bib42","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1016\/j.clinthera.2020.03.005","article-title":"Possible influence of the route of treatment administration on treatment adherence in patients with multiple sclerosis","volume":"42","author":"Sanchez Martinez","year":"2020","journal-title":"Clin Ther"}],"container-title":["Obesity Pillars"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667368126000343?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667368126000343?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:30:31Z","timestamp":1787988631000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667368126000343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":41,"alternative-id":["S2667368126000343"],"URL":"https:\/\/doi.org\/10.1016\/j.obpill.2026.100278","relation":{},"ISSN":["2667-3681"],"issn-type":[{"value":"2667-3681","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient preferences for pharmacological treatments for obesity: The VOICE study","name":"articletitle","label":"Article Title"},{"value":"Obesity Pillars","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.obpill.2026.100278","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Eli Lilly and Company. Published by Elsevier Inc. on behalf of Obesity Medicine Association.","name":"copyright","label":"Copyright"}],"article-number":"100278"}}